We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Pocket-Sized Zinc Deficiency Test Evaluated

By LabMedica International staff writers
Posted on 09 Oct 2019
Easy-to-perform, relatively inexpensive blood diagnostics have transformed at-home healthcare for some patients, but they require analytical equipment and are not easily adapted to measuring other biomarkers.

The requirement for reliable quantification in complex sample types, such as blood, has been a critical roadblock in developing and deploying inexpensive, minimal-equipment diagnostics. More...
A pocket-sized zinc deficiency test has been developed that could be taken to remote regions where masses are malnourished with no complex transport or preservation necessary.

A team of scientists working with the Georgia Institute of Technology (Atlanta, GA, USA) developed a platform for inexpensive, easy-to-use diagnostics that uses cell-free expression to generate colored readouts that are visible to the naked eye, yet quantitative and robust to the interference effects seen in complex samples. The platform includes plasmids, which are loops of DNA. They are not the same DNA strands behind reproduction and cell construction, but function instead like nano-organs with genetic programs that normally guide bacterial cell processes. The team engineered their own plasmids to direct other parts extracted from bacteria to make the blood test work.

The test uses a signal molecule that is partly a big sugar and starts out yellow, but once the plasmid makes an enzyme that cleaves the sugar, the molecule turns purple. Zinc levels regulate how much enzyme is made more zinc means more enzyme and more purple. If the test remains yellow, zinc is perilously low. The new technology showed high potential as a basis for an inexpensive, easy malnutrition test for use in the field that could be expanded to include many vital nutrients and other health indicators.

The new test is freeze-dried to a powder that is kept at room temperatures, could be read in the field, and may be suitable for precise analysis with an applicable smartphone app. It could overcome the clinical and logistical travails of other tests, including refrigerated transport to the field or back to a laboratory, as well as lost time. The test not only detects zinc, but also quantifies its clinically relevant levels, which is necessary to detect malnourishment and is one of the new test's main innovations. Aid agencies could use a field version of the test to get immediate information to quickly influence policy decisions on nutritional interventions.

Mark P. Styczynski, PhD, an associate professor and first author of the study, said, “In the developing world today, many people may get enough calories but miss out on a lot of nutrients. You can look at someone and tell if they're getting enough calories but not if they're getting sufficient amounts of developmentally important nutrients. The impact is greatest on pregnant mothers, as well as children under the age of 5, which is when they have the highest mortality.” The study was published on September 4, 2019, in the journal Science Advances.

Related Links:
Georgia Institute of Technology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gold Member
Platelet Function Analyzer
PL-12
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.